Jubilant Biosys Ltd, a subsidiary of Jubilant Life Sciences Ltd, and Checkpoint Therapeutics, Inc., a subsidiary of Fortress Biotech, Inc., have signed an exclusive, worldwide license agreement under which Jubilant Biosys will out-license to Checkpoint a family of patents covering compounds that inhibit BRD4, a member of the BET (bromodomain and extra terminal) domain for cancer treatment. The deal includes an upfront payment of $2 million and contingent preclinical, clinical and regulatory payments, including commercial milestones totalling up to $180 million.

Jubilant Biosys will also receive research funding and royalty payments on successful commercialization of the compounds. Checkpoint will assume all further preclinical, clinical development and commercialization responsibilities.

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in manufacture and supply of active pharmaceutical ingredients, solid dosage formulations, radiopharmaceuticals, allergy therapy products, and life science ingredients. It also provides services in contractcmanufacturing of sterile injectables and drug discovery solutions.

Source: Jubilant Biosys